Syndax Pharmaceuticals Inc
SNDX· Nasdaq
SNDXSyndax Pharmaceuticals Inc
Filed Mar 1, 2022 · 10-K · 60 days after period end · 0001564590-22-008112
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $126.58M | $380.00K | $380.00K | $380.00K |
| Net Income | $96.20M | -$20.42M | -$14.00M | -$18.84M |
| EPS Diluted | — | -$0.44 | -$0.44 | $0.70 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Mar 1, 2022 · 60 d after period end
